Announced
Completed
Financials
Sources
Tags
biotechnology
Private
health care
Single Bidder
Majority
Acquisition
Completed
Friendly
United States
pharmaceutical
Biotechnology
Domestic
Synopsis
Kriya Therapeutics, a fully integrated gene therapy company, completed the acquisition of Redpin Therapeutics, a privately held biotechnology company. Financial terms were not disclosed. “Redpin has a built a breakthrough, validated chemogenetics approach that could have significant potential in the targeted treatment of neurological disorders. Kriya Therapeutics is the perfect company to take this leading ion channel-based platform forward and deliver an effective treatment option for patients. We look forward to working with the Kriya team to progress these unique targeted therapies to patients in need as rapidly as possible,” Elma Hawkins, Redpin Therapeutics President, Chief Executive Officer and Co-founder.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.